More News

Genentech Initiates Two Phase III Trials of Faricimab in ME with RVO
Genentech Initiates Two Phase III Trials of Faricimab in ME with RVO

Genentech has initiated two Phase III trials of faricimab in patients with macular edema (ME) following retinal vein occlusion. The randomized, multicenter, double-masked, global COMINO and BALATON...

Betaliq Starts Enrollment in Phase II Trial of EyeSol-based Beta Blockers in Glaucoma
Betaliq Starts Enrollment in Phase II Trial of EyeSol-based Beta Blockers in Glaucoma

Betaliq, of Tampa, Florida, has begun enrollment in a Phase II clinical trial of two beta blockers formulated with Novaliq’s EyeSol technology for the treatment of glaucoma or ocular hypertension, ...

EyeYon’s EndoArt Implant Gains ‘Innovative’ Designation in China
EyeYon’s EndoArt Implant Gains ‘Innovative’ Designation in China

EyeYon Medical’s EndoArt synthetic implant for chronic corneal edema has received an innovative device designation in China, making it the first ophthalmic device granted breakthrough status in bot...

CHMP Recommends EU approval of Roche’s Enspryng for NMOSD
CHMP Recommends EU approval of Roche’s Enspryng for NMOSD

Swiss pharmaceutical company Roche announced April 23 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Enspryng (satralizum...

Ocugen Raises $100 Million in Registered Direct Offering of Common Stock
Ocugen Raises $100 Million in Registered Direct Offering of Common Stock

Ocugen announced April 23 that it had entered into agreements with health care-focused institutional investors for the sale of 10 million shares of its common stock at $10 per share in a registered...

Aerie Gains Market Approval for Roclanda in Great Britain
Aerie Gains Market Approval for Roclanda in Great Britain

Aerie Pharmaceuticals announced April 19 that Roclanda (sold in the US as Rocklatan) had received marketing authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) in Grea...

SparingVision Acquires GAMUT, Licenses Cone-Specific Promoter Technology from AGTC
SparingVision Acquires GAMUT, Licenses Cone-Specific Promoter Technology from AGTC

French company SparingVision announced April 20 that it had entered into an agreement to acquire GAMUT Therapeutics, of Paris, which is developing a gene-independent approach to treat the later sta...

Ripple Therapeutics Treats First Patient in Phase II Trial of DME, RVO Candidate
Ripple Therapeutics Treats First Patient in Phase II Trial of DME, RVO Candidate

Ripple Therapeutics announced April 20 that it had dosed the first patient in RIPPLE-1, a Phase II trial evaluating IBE-814 IVT, a dexamethasone implant targeting inflammatory retinal diseases. The...

Gemini Names Samuel Barone, MD, as Chief Medical Officer
Gemini Names Samuel Barone, MD, as Chief Medical Officer

Gemini Therapeutics, of Cambridge, Massachusetts, reported April 12 that it had appointed Samuel Barone, MD, as chief medical officer (CMO). Barone previously held roles as senior vice president of...

Market Scope Tracking Status of 2021 Ophthalmic Meetings
Market Scope Tracking Status of 2021 Ophthalmic Meetings

Market Scope is tracking the status of 2021 ophthalmic meetings as the world tries to recover from COVID-19. Here is the latest information: Organization Status Date Location More Information Glauc...

Tesseract Health Closes Oversubscribed $80 Million Series B Financing
Tesseract Health Closes Oversubscribed $80 Million Series B Financing

Tesseract Health announced April 20 that it had raised $80 million in an oversubscribed Series B financing round to advance its Tesseract iC eye-imaging diagnostic technology platform. The Tesserac...

Nanodropper Completes $1.4 Million Seed Funding Round
Nanodropper Completes $1.4 Million Seed Funding Round

Nanodropper, which offers a first-of-its-kind bottle adaptor that reduces eye drop size, announced April 19 that it had completed a $1.4 million seed round. The Rochester, Minnesota, company said G...

Alcon Reveals 2025 Target of $10 Billion in Revenue
Alcon Reveals 2025 Target of $10 Billion in Revenue

Alcon used its recent Capital Markets Day to outline the company’s roadmap to achieving $10 billion in sales by 2025. Switzerland-registered, Texas-based Alcon recorded sales of $6.8 billion in pan...

Ophthalmic In-Person Meetings Return—to Mixed Enthusiasm
Ophthalmic In-Person Meetings Return—to Mixed Enthusiasm

Ophthalmic industry participants are eager to return to in-person meetings in 2021, though about 66 percent plan to commit less resources to the 2021 ASCRS meeting compared with 2019, according to ...

OFF’s Asian Retina Forum Highlights Rapid Pace of Licensing in China
OFF’s Asian Retina Forum Highlights Rapid Pace of Licensing in China

The Asian forums presented as part of the Ophthalmology Futures Forums series typically feature engaging and insightful panel discussions on the region’s eye care markets. The 2021 Asian Retina For...

Rayner Gains US FDA Approval of RayOne EMV Enhanced Monofocal IOL
Rayner Gains US FDA Approval of RayOne EMV Enhanced Monofocal IOL

Rayner announced March 21 that the RayOne EMV intraocular lens had been granted US FDA approval. The UK-based company describes the enhanced monofocal lens as a fully preloaded nondiffractive IOL d...

Bausch + Lomb Dry Eye Candidate Licensed from Novaliq Meets  All Phase III Endpoints
Bausch + Lomb Dry Eye Candidate Licensed from Novaliq Meets All Phase III Endpoints

Bausch + Lomb, a division of Canada’s Bausch Health, and Germany’s Novaliq announced April 13 statistically significant topline data from the first Phase III trial of NOV03 (perfluorohexyloctane) f...

Horizon Gets FDA’s Go-ahead to Resupply Tepezza for TED Patients
Horizon Gets FDA’s Go-ahead to Resupply Tepezza for TED Patients

Horizon Therapeutics announced March 30 that the US FDA had approved a prior approval supplement (PAS) giving Horizon authorization to manufacture more Tepezza, resulting in an increased number of ...

Surgical Instruments Maker Katena Buys ASICO, Building on Roster of Recent Acquisitions
Surgical Instruments Maker Katena Buys ASICO, Building on Roster of Recent Acquisitions

Katena Products announced April 14 that it had purchased fellow ophthalmic surgical instrument maker ASICO, of Westmont, Illinois. The companies said ASICO’s product portfolio comprises more than 1...

Pixium, Second Sight Merger Deal Falls Apart Over Private Placement
Pixium, Second Sight Merger Deal Falls Apart Over Private Placement

Pixium Vision announced April 3 that its merger deal with fellow retinal implant company Second Sight had been scrapped, following a controversial private placement closed by Second Sight. The Fren...

Select US FDA Approvals and Clearances in March 2021
Select US FDA Approvals and Clearances in March 2021

The US FDA granted three clearances through the ophthalmic division using the 510(k) pathway in March 2021, according to the agency’s database. The notable clearance of the three is for J&J Vision’...

Qlaris Bio Enrolls First Patient in Phase I/II Studies of Novel Glaucoma Approach
Qlaris Bio Enrolls First Patient in Phase I/II Studies of Novel Glaucoma Approach

Qlaris Bio announced April 15 that it had enrolled the first patient in the Phase I/II clinical program for QLS-101, an investigational therapy designed to lower intraocular pressure (IOP) by reduc...

AAO, NEI, Others Urge Manufacturers to Standardize Digital Imaging
AAO, NEI, Others Urge Manufacturers to Standardize Digital Imaging

The American Academy of Ophthalmology published a report April 5 urging ophthalmic imaging device manufacturers to standardize image formats to comply with the Digital Imaging and Communications in...

Emerging Companies Pursuing Ophthalmic Indications, April 2021
Emerging Companies Pursuing Ophthalmic Indications, April 2021

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease. Company Location About Hovione Lisbon, Portugal The company announced March 17 that it had c...

AffaMed Leads Latest Ophthalmic Fundraising Efforts with $170 Million Series B
AffaMed Leads Latest Ophthalmic Fundraising Efforts with $170 Million Series B

AffaMed, based in Hong Kong and Shanghai, led recent fundraising efforts by ophthalmic companies, with $170 million raised in a Series B round. Funding for the past four weeks totaled $667.5 millio...

OFF Asian Forum Highlights Surge in Ophthalmology Despite Pandemic
OFF Asian Forum Highlights Surge in Ophthalmology Despite Pandemic

The Asian Forum—held a day after the Asian Retina Forum and part of the Ophthalmology Futures Forum series—covered a range of topics. The virtual event March 26 focused on the region’s continued mo...

Backlog of 6 Million Cataract Surgeries Will Help Drive IOL Market through 2026
Backlog of 6 Million Cataract Surgeries Will Help Drive IOL Market through 2026

Pandemic-impacted 2020 led to a backlog of more than 6 million cataract surgeries globally, as procedures declined 25 percent to 22 million, the lowest number since 2010, mainly due to COVID-relate...

New Products Slow to Change US Cataract Pharmaceuticals Market
New Products Slow to Change US Cataract Pharmaceuticals Market

US cataract surgeons showed a preference for incremental over revolutionary change in drug delivery by choosing a new eye drop twice as often as competing new products providing multi-week release ...

RegeneRx’s RGN-259  Dry Eye Candidate Fails  to Meet Endpoints  In Third Phase III Trial
RegeneRx’s RGN-259 Dry Eye Candidate Fails to Meet Endpoints In Third Phase III Trial

Maryland-based RegeneRx Biopharmaceuticals announced March 18 that its RGN-259 eye drops for dry eye did not meet primary outcome measures in a third Phase III trial, ARISE-3. According to clinical...

Ophthalmic Laser Market Expected to Total $376.4 Million in 2021
Ophthalmic Laser Market Expected to Total $376.4 Million in 2021

Global revenue for ophthalmic lasers—photocoagulation, photodisruption (YAG), and SLT—along with maintenance, accessories, and endoprobes, will total over $376.4 million in 2021 and grow at a compo...

Zeiss’ $180 Million Innovation Center Opens Near San Francisco
Zeiss’ $180 Million Innovation Center Opens Near San Francisco

German company Zeiss announced March 31 that it had opened its Zeiss Innovation Center, a newly constructed facility built on 13.5 acres in Dublin, California, near San Francisco. The $180 million ...

Market Scope Weekly Ophthalmic Surgeon Poll, April 2021
Market Scope Weekly Ophthalmic Surgeon Poll, April 2021

Aerie Gains Market  Approval for Roclanda in Great Britain
Aerie Gains Market Approval for Roclanda in Great Britain

Aerie Pharmaceuticals announced April 19 that Roclanda (sold in the US as Rocklatan) had received marketing authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) in Grea...

April 2021 Ophthalmic News Briefs
April 2021 Ophthalmic News Briefs

Alimera Sciences announced April 14 that China’s Ocumension Therapeutics had paid $10 million up front to license Alimera’s 0.19 mg fluocinolone acetonide intravitreal implant, which Alimera market...

US Cataract Pharmaceuticals Evolve in Drug Delivery
US Cataract Pharmaceuticals Evolve in Drug Delivery

US cataract surgeons showed a preference for incremental improvement in drug delivery over revolutionary change in the first full year for three new corticosteroid products to manage inflammation a...

Katena Buys ASICO, Building on Roster of Recent Acquisitions
Katena Buys ASICO, Building on Roster of Recent Acquisitions

Katena Products announced April 14 that it had purchased fellow ophthalmic surgical instrument maker ASICO, of Westmont, Illinois. The companies said ASICO’s product portfolio comprises more than 1...

Alimera Licenses its Steroid Implant to Ocumension for Asian Markets, Receives $20 Million
Alimera Licenses its Steroid Implant to Ocumension for Asian Markets, Receives $20 Million

Alimera Sciences announced April 14 that China’s Ocumension Therapeutics had paid $10 million up front to license Alimera’s 0.19 mg fluocinolone acetonide intravitreal implant, which Alimera market...

Bausch + Lomb Dry Eye Candidate Licensed from Novaliq Meets All Endpoints in Phase III Trial
Bausch + Lomb Dry Eye Candidate Licensed from Novaliq Meets All Endpoints in Phase III Trial

Bausch + Lomb, a division of Canada’s Bausch Health, and Germany’s Novaliq announced April 13 statistically significant topline data from the first Phase III trial of NOV03 (perfluorohexyloctane) f...

AAO, NEI, Others Urge Ophthalmic Equipment Manufacturers to Standardize Digital Imaging
AAO, NEI, Others Urge Ophthalmic Equipment Manufacturers to Standardize Digital Imaging

The American Academy of Ophthalmology published a report April 5 urging ophthalmic imaging device manufacturers to standardize image formats to comply with the Digital Imaging and Communications in...

J&J Vision Surgical Gains US Clearance for Veritas Next-Generation Phaco System
J&J Vision Surgical Gains US Clearance for Veritas Next-Generation Phaco System

Johnson & Johnson Vision Surgical gained US FDA 510(k) clearance on March 12 for its Veritas Vision System. The phacoemulsification system is an updated version of the company’s WhiteStar Signature...

Alcon Introduces UV-Filtering Versions of PanOptix, Vivity IOLs in Canada
Alcon Introduces UV-Filtering Versions of PanOptix, Vivity IOLs in Canada

Alcon announced on April 12 that it had launched in Canada four next-generation IOLs to provide ultraviolet (UV)-filtering hydrophobic protection. The models are the AcrySof IQ PanOptix UV intraocu...

AGTC Licenses X-Linked Retinoschisis Gene Therapy Program to TeamedOn
AGTC Licenses X-Linked Retinoschisis Gene Therapy Program to TeamedOn

Applied Genetic Technologies Corporation (AGTC) announced April 13 that it had reached a licensing deal with TeamedOn International to advance a gene therapy candidate to treat X-linked retinoschis...

Apellis Sees Positive Results with Pegcetacoplan at 24 Months in GA
Apellis Sees Positive Results with Pegcetacoplan at 24 Months in GA

Apellis Pharmaceuticals on April 13 reported 24-month data from its Phase Ib study of pegcetacoplan. The targeted C3 therapy is under investigation as a treatment for bilateral advanced geographic ...

Qlaris Bio Enrolls First Patient in Phase I/II Studies of Glaucoma Candidate
Qlaris Bio Enrolls First Patient in Phase I/II Studies of Glaucoma Candidate

Qlaris Bio announced April 15 that it had enrolled the first patient in the Phase I/II clinical program for QLS-101, an investigational therapy designed to lower intraocular pressure (IOP) by reduc...

Harrow Health Announces Public Offering of $50 Million in Senior Notes
Harrow Health Announces Public Offering of $50 Million in Senior Notes

Harrow Health announced April 15 that it has commenced an underwritten registered public offering of $50 million in senior notes due 2026. The company, based in Nashville, Tennessee, said it expect...

Bionic Sight Reports Light Sensitivity in RP Patients Treated with Gene Therapy Candidate
Bionic Sight Reports Light Sensitivity in RP Patients Treated with Gene Therapy Candidate

Bionic Sight, of New York, reported March 30 that the first four patients treated with its gene therapy candidate for retinitis pigmentosa were able to detect light and motion, and two could detect...

US FDA Approves Bausch + Lomb’s ClearVisc Dispersive OVD
US FDA Approves Bausch + Lomb’s ClearVisc Dispersive OVD

Bausch + Lomb announced April 7 that the US FDA had approved its ClearVisc dispersive ophthalmic viscosurgical device (OVD) for use in ophthalmic surgery. OVDs aid in cataract extraction and intrao...

Chinese Regulators Approve IND for Neurophth’s LHON Gene Therapy Candidate
Chinese Regulators Approve IND for Neurophth’s LHON Gene Therapy Candidate

Neurophth Biotechnology announced April 1 that the China National Medical Products Administration had approved the company’s investigational new drug (IND) application for its gene therapy candidat...

Oxurion Secures Capital Commitment of up to $35.8 Million from Negma Group
Oxurion Secures Capital Commitment of up to $35.8 Million from Negma Group

Belgium’s Oxurion announced April 6 that it had agreed to a capital commitment of up to €30 million (US $35.8 million) from Negma Group. Negma Group is a growth-focused debt and equity firm based i...

ProQR Raises $103.5 Million After Full Exercise of Underwriters’ Option
ProQR Raises $103.5 Million After Full Exercise of Underwriters’ Option

Netherlands-based ProQR Therapeutics announced April 5 that it had closed an underwritten public offering of 13,846,154 ordinary shares at $6.50 per share. Underwriters fully exercised their option...

Want to Read Locked Articles?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more